
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is well-positioned for growth with strong financials, FDA approval, and expansion plans in multiple markets. Their inclusion in ACS guidelines and plans to offer testing for a wider range of tumor types and lower costs by 2028 provide a solid foundation for future success. However, the company should closely monitor competition in the precision oncology diagnostics market and ensure successful launches of new tests.
Bears say
Guardant Health is facing several risks that could potentially impact its growth and profitability. These include potential market maturation and saturation, uncertainty surrounding future recommendations from the U.S. Preventative Services Task Force, and concerns about competition and potential litigation in the precision oncology space. While Guardant has shown impressive growth so far, there are potential challenges ahead, such as the risk of overvaluation and volatility in the precision oncology market and the company's reliance on a few key products and partnerships. Additionally, there are potential risks in the company's development, reimbursement, and commercialization strategies for its new MRD and early detection tests.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares